explore -WSS

explore

author：comprehensive 2025-09-29 13:09:53 - browse：9119

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Why Congress must ban federal programs from using QALYs

WSS

Tocagen's brain cancer gene therapy trial continues. Investors worry

Congressmen charge Covid hearing ‘could have been an email’

Mass General totes up its waste in a move to tackle climate change

Affordable Connectivity Program vital to health care, experts say

Time to name cancers by genetics, not organ of origin, expert says

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Cancer drug shortages should be causing more outrage

New Ultima Genomics DNA sequencer can read genome for $100

What does generative AI mean for health care? We asked experts

Indian pharmaceutical industry in denial over drug

Walensky prepares to leave CDC — and Congress — behind

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Guidelines to prevent youth baseball injuries need more muscle

Ending racial health disparities hinges on penalties, political will

How to save PrEP access — and even expand it

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

explore

Juul spent big to court Black leaders to promote its e

Quicker fix for pulse oximeters urged during FDA public meeting

Awakening the world to the whoosh: A patient's crusade

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Do digital therapeutics have a future in medicine?

FDA drug safety: Singulair case shows systemic surveillance flaws

hotspot

leisure time

hotspot

Wikipedia